newsfilter
← Latest News
PR Newswire·

New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]

Independent biopharmaceutical company Specialised Therapeutics is pleased to announce that NIKTIMVO® (axatilimab) has been approved for use in...